

Kentucky Medicaid Substance Use Treatment Pharmacy Prior Authorization Form For Buprenorphine Products

- **Buprenorphine Product prior authorizations for substance use treatment can ONLY be requested by AUTHORIZED PHYSICIANS using This Form.**
- For **Pain Management** - Please use the [Kentucky Medicaid Pharmacy Prior Authorization Form](#) (only limited buprenorphine products are approved for pain management).

Length of authorization: **Induction Request:** Ten (10) days' supply for three (3) fills, followed by fourteen (14) days' supply for two (2) fills; **Maintenance Request:** Six (6) months

Complete each section legibly and completely. Include any supporting documents as needed (lab results, chart notes, etc.).

Please fax completed form to the corresponding fax number of the health plan partner your patient is currently enrolled. Additional prior authorization forms can be found by clicking on hyperlinks provided to the right.	Plan:	Phone number:	Fax number:
	<input type="checkbox"/> Fee-For-Service (Magellan)	1 (800) 477-3071	1 (800) 365-8835
	<input type="checkbox"/> Anthem Medicaid	1 (855) 661-2028	1 (855) 875-3627
	<input type="checkbox"/> Aetna Better Health	1 (855) 300-5528	1 (855) 799-2550
	<input type="checkbox"/> Humana CareSource	1 (855) 852-7005	1 (866) 930-0019
	<input type="checkbox"/> Passport Health Plan	1 (844) 380-8831	1 (844) 802-1406
	<input type="checkbox"/> WellCare of Kentucky	1 (877) 389-9457	1 (855) 620-1868
I. Member Information	Member Name:		Date of Birth:
	Member ID:		Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female
	Address: City, State, Zip:		Phone:
II. Prescriber Information	Name:		DEA:
	Office Contact Name:		XDEA:
	Office Address: City, State, Zip:		NPI:
	Phone:		FAX:
	1. Prescriber is enrolled as a valid Medicaid prescriber? <input type="checkbox"/> Yes <input type="checkbox"/> No		
	2. Prescriber certifies they are treating the patient for a substance use disorder and billing Medicaid for such service(s) through the member's health plan? <input type="checkbox"/> Yes <input type="checkbox"/> No		
3. Prescriber is compliant with all stipulations in the practice act regulation (201 KAR 9:270) when dispensing buprenorphine products? <input type="checkbox"/> Yes <input type="checkbox"/> No			
III. Diagnosis Criteria	Diagnosis:		ICD-10 Code:
	1. Patient has signed an informed consent or treatment contract? <input type="checkbox"/> Yes <input type="checkbox"/> No		
	2. Patient's treatment plan includes at least once monthly visits with the treating physician or their qualified agent? <input type="checkbox"/> Yes <input type="checkbox"/> No		
	3. Prescriber has explained the risks and benefits of using buprenorphine containing products to the patient, along with the risk of using these products with alcohol, stimulants, other opioids, or benzodiazepines? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Other Relevant Diagnoses:			
Please indicate whether this is a: <input type="checkbox"/> INITIAL Request <input type="checkbox"/> REAUTHORIZATION (REFILL) Request with current plan			
Check One: <input type="checkbox"/> Induction <input type="checkbox"/> Maintenance		Induction Date (required):	
IV. REQUESTED BUPRENORPHINE PRODUCT			
Medication Requested:			
Directions for Use:			
Dosage Strength Requested:		Quantity:	Total mg Per Day:
Days' Supply:		Duration of Therapy:	
BUPRENORPHINE SINGLE INGREDIENT REQUESTS ONLY: (clinical criteria must meet all initial criteria and ONE (1) of the following)			
Check One: <input type="checkbox"/> Patient is pregnant <input type="checkbox"/> Two (2) day induction to therapy <input type="checkbox"/> Hypersensitivity to naloxone			
<u>Required for Review:</u> Documentation illustrating hypersensitivity reaction to naloxone, if applicable.			
Female Patients Only:			
1. Is the patient pregnant or nursing? <input type="checkbox"/> Yes <input type="checkbox"/> No			
If YES , prescriber must be certified in addiction medicine, psychiatry, obstetrics, or maternal-fetal medicine by the American Board of Addiction Medicine (ABAM), the American Board of Medical Specialties (ABMS), or an American Osteopathic Association (AOA) certifying board OR documentation must be submitted stating that the prescriber has consulted with such a certified provider.			
2. Has patient been counseled on the risks of neonatal abstinence syndrome? <input type="checkbox"/> Yes <input type="checkbox"/> No			
<u>Required for Review:</u> Documentation of recent pregnancy test or inability to conceive and/or documentation of counseling as to the risk of neonatal abstinence syndrome by a certified prescriber.			

KASPER Request Number:	Date Last Queried:	Number of Concomitant Narcotic Prescriptions:	Date of Last Controlled Substance Filled:
------------------------	--------------------	---	---

Initial KASPER should include controlled substance fill history for last twelve (12) months.

V. INITIAL TREATMENT REQUESTS ONLY (if request is for continuation therapy skip to Section VI)

- Has prescriber identified any opioid, benzodiazepine, sedative, or stimulant prescribed medications fourteen (14) days prior to requested initiation of buprenorphine therapy? Yes No If yes, have they been discontinued? Yes No
If no, please refer to criteria for documentation that must be submitted for approval. For concomitant use, the prescriber must be certified through the American Board of Addiction Medicine (ABAM), the American Board of Medical Specialties (ABMS) in psychiatry, OR if not, they have consulted with a certified practitioner. Please document your specialty or the name and specialty of consulted prescriber.
- Prescriber has included documentation of an initial assessment and full treatment plan including acceptable documentation of monitoring and behavioral and psychosocial therapy drug abuse counseling services? Yes No
Include induction phase and titration schedule proposed to determine the appropriate level of dosage, a stabilization phase leading to a step down tapering phase, and a discontinuation phase or evidence and support for continued use, and counseling documentation (see Section VII below).
- Prescriber has included documentation that the patient is being referred or already started receiving behavioral and psychosocial therapy services? Yes No
- Prescriber has obtained the below KASPER report no earlier than two (2) days prior to the date of this request? Yes No

VI. REAUTHORIZATION (REFILL) REQUESTS ONLY (with current plan)

- The prescriber has previously submitted all required initial treatment documentation? Yes No
- The prescriber has included documentation of monthly negative urine tests for opiates since previous authorization? Yes No
All monthly urine drug screens since previous authorization must be provided to be considered a complete request.
- Patient has been compliant with **NO GAPS** in therapy since initial authorization? Yes No (if no, attach explanation)
- The prescriber has included documentation that demonstrates evaluation of patient's dosage and/or appropriation chart documentation and clinical reasoning for continuation? Yes No (dose evaluations are required every three (3) months after initial fill at 4mg or greater)
- The patient has continued active participation in evidence based drug abuse counseling methods? Yes No (**attach documentation**) **Note:** It is expected that the patient will actively participate in at least one (1) counseling and self-help group activity per week for the first three (3) months of continual care, then decrease at the practitioner's discretion to a minimum of once per month for the patient who is progressing and compliant with care. For established patients with no session in the past month, approval will be granted for one (1) month, if all other criteria is met, and no additional fills shall be approved until counseling has resumed.

Required for review: Documentation of all monitoring tools (urine analysis/drug screen) including medication compliance checks that occurred prior to or in between requests. Any abnormal findings must be explained.

Complete the information below regarding KASPER reports: (each report prior to the last PA submitted must be listed; these should be run monthly)

Report #	Query Date	KASPER Request Number	Report #	Query Date	KASPER Request Number
1			4		
2			5		
3			6		

Tapering Therapy (must be attempted after every six (6) month interval of treatment) - Only complete if applicable:

Has the patient attempted a two (2) week trial of a lower buprenorphine dose? Yes No (if no, request will be denied)
Include dose level attempted, date and length of trial: (include documentation if attempt failed) _____

VII. COUNSELING DOCUMENTATION (the following must be submitted with each PA request)

Required for Review: Documentation of the physician rendering counseling must be submitted with each request if the prescribing physician is not a psychiatrist or certified addiction specialist. If another physician is providing counseling, a letterhead from that individual must be submitted confirming the patient is undergoing active counseling (including objective psychosocial and behavioral modification).

Other Pertinent Information: (attach additional pages if needed) _____

I attest, by signature, that the above information is true and accurate to the best of my knowledge and has been documented appropriately in the patient's medical records.

Prescriber Signature:	Date:
-----------------------	-------